Cargando…
Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
Checkpoint inhibitor-related pneumonitis (CIP) is one of the most important immune checkpoint inhibitors side effects, and it is rare but fatal. Identifying patients at risk of refractory CIP before the start of CIP therapy is important for controlling CIP. We retrospectively analyzed the clinical d...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889196/ https://www.ncbi.nlm.nih.gov/pubmed/36637978 http://dx.doi.org/10.1097/CJI.0000000000000451 |
_version_ | 1784880677926207488 |
---|---|
author | Tan, Peixin Huang, Wei He, Xinyan Lv, Fengquan Cui, Yanhai Du, Shasha |
author_facet | Tan, Peixin Huang, Wei He, Xinyan Lv, Fengquan Cui, Yanhai Du, Shasha |
author_sort | Tan, Peixin |
collection | PubMed |
description | Checkpoint inhibitor-related pneumonitis (CIP) is one of the most important immune checkpoint inhibitors side effects, and it is rare but fatal. Identifying patients at risk of refractory CIP before the start of CIP therapy is important for controlling CIP. We retrospectively analyzed the clinical data of 60 patients with lung cancer who developed CIP. Refractory CIP was defined as CIP with poor response to corticosteroid treatment, including CIP not relieved with corticosteroid administration or CIP recurrence during the corticosteroid tapering period. We analyzed clinical characteristics, peripheral blood biomarkers, treatment, and outcomes in nonrefractory and refractory CIP. Risk factors associated with refractory CIP were assessed. Among 60 patients with CIP, 16 (26.7%) had refractory CIP. The median onset time for patients with nonrefractory and those with refractory CIP was 16.57 (interquartile range [IQR], 6.82–28.14) weeks and 7.43 (IQR, 2.71–19.1) weeks, respectively. The level of lactate dehydrogenase (LDH) was significantly higher in the refractory CIP group at baseline (255 [222, 418] vs. 216 [183, 252], P=0.031) and at CIP onset (321.5 [216.75, 487.5] vs. 219 [198. 241], P=0.019). An LDH level >320 U/L at CIP onset was an independent risk factor of refractory CIP (odds ratio [OR], 8.889; 95% confidence interval [CI]: 1.294–61.058; P=0.026). The incidence of refractory CIP is high among patients with CIP. An increased LDH level at CIP onset is independently associated with refractory CIP. Monitoring LDH levels during immune checkpoint inhibitors treatment is recommended. |
format | Online Article Text |
id | pubmed-9889196 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-98891962023-02-07 Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer Tan, Peixin Huang, Wei He, Xinyan Lv, Fengquan Cui, Yanhai Du, Shasha J Immunother Clinical Studies Checkpoint inhibitor-related pneumonitis (CIP) is one of the most important immune checkpoint inhibitors side effects, and it is rare but fatal. Identifying patients at risk of refractory CIP before the start of CIP therapy is important for controlling CIP. We retrospectively analyzed the clinical data of 60 patients with lung cancer who developed CIP. Refractory CIP was defined as CIP with poor response to corticosteroid treatment, including CIP not relieved with corticosteroid administration or CIP recurrence during the corticosteroid tapering period. We analyzed clinical characteristics, peripheral blood biomarkers, treatment, and outcomes in nonrefractory and refractory CIP. Risk factors associated with refractory CIP were assessed. Among 60 patients with CIP, 16 (26.7%) had refractory CIP. The median onset time for patients with nonrefractory and those with refractory CIP was 16.57 (interquartile range [IQR], 6.82–28.14) weeks and 7.43 (IQR, 2.71–19.1) weeks, respectively. The level of lactate dehydrogenase (LDH) was significantly higher in the refractory CIP group at baseline (255 [222, 418] vs. 216 [183, 252], P=0.031) and at CIP onset (321.5 [216.75, 487.5] vs. 219 [198. 241], P=0.019). An LDH level >320 U/L at CIP onset was an independent risk factor of refractory CIP (odds ratio [OR], 8.889; 95% confidence interval [CI]: 1.294–61.058; P=0.026). The incidence of refractory CIP is high among patients with CIP. An increased LDH level at CIP onset is independently associated with refractory CIP. Monitoring LDH levels during immune checkpoint inhibitors treatment is recommended. Lippincott Williams & Wilkins 2023 2023-01-16 /pmc/articles/PMC9889196/ /pubmed/36637978 http://dx.doi.org/10.1097/CJI.0000000000000451 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Clinical Studies Tan, Peixin Huang, Wei He, Xinyan Lv, Fengquan Cui, Yanhai Du, Shasha Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer |
title | Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer |
title_full | Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer |
title_fullStr | Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer |
title_full_unstemmed | Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer |
title_short | Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer |
title_sort | risk factors for refractory immune checkpoint inhibitor-related pneumonitis in patients with lung cancer |
topic | Clinical Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889196/ https://www.ncbi.nlm.nih.gov/pubmed/36637978 http://dx.doi.org/10.1097/CJI.0000000000000451 |
work_keys_str_mv | AT tanpeixin riskfactorsforrefractoryimmunecheckpointinhibitorrelatedpneumonitisinpatientswithlungcancer AT huangwei riskfactorsforrefractoryimmunecheckpointinhibitorrelatedpneumonitisinpatientswithlungcancer AT hexinyan riskfactorsforrefractoryimmunecheckpointinhibitorrelatedpneumonitisinpatientswithlungcancer AT lvfengquan riskfactorsforrefractoryimmunecheckpointinhibitorrelatedpneumonitisinpatientswithlungcancer AT cuiyanhai riskfactorsforrefractoryimmunecheckpointinhibitorrelatedpneumonitisinpatientswithlungcancer AT dushasha riskfactorsforrefractoryimmunecheckpointinhibitorrelatedpneumonitisinpatientswithlungcancer |